Cortney Caudill

Cortney Caudill

No open positions remaining

Net worth: 469 440 $ as of 31/05/2026

Health Technology
Consumer Services

Profile

Cortney Caudill formerly worked at SAMSUNG BIOLOGICS Co., Ltd., as Director-Business Development Technology, Genentech, Inc., as Principal, VaxGen, Inc., as Principal, Baxalta Schweiz AG, as Head-Drug Product External Manufacturing Network from 2014 to 2016, Spyre Therapeutics, Inc., as Chief Product Officer in 2023, and Halozyme Therapeutics, Inc., as Chief Operating Officer & Senior Vice President from 2025 to 2026.
Ms. Caudill received her Masters Business Admin degree from Fordham University and undergraduate degree from The University of Texas at Austin.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
10/03/2026 7,055 ( 0.01% ) 469 440 $ 31/05/2026

Former positions of Cortney Caudill

CompaniesPositionEnd
HALOZYME THERAPEUTICS, INC. Chief Operating Officer 30/06/2026
SPYRE THERAPEUTICS, INC. Chief Tech/Sci/R&D Officer 06/01/2023
Baxalta Schweiz AG
Corporate Officer/Principal 01/02/2016
Corporate Officer/Principal -
Corporate Officer/Principal -
See the detail of Cortney Caudill's experience

Training of Cortney Caudill

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

17

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies8

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Baxalta Schweiz AG

  1. Stock Market
  2. Insiders
  3. Cortney Caudill